{"id":5248,"date":"2019-11-13T10:13:13","date_gmt":"2019-11-13T15:13:13","guid":{"rendered":"https:\/\/www.campbellslegal.com\/?p=5248"},"modified":"2020-01-20T16:32:44","modified_gmt":"2020-01-20T21:32:44","slug":"norwich-pharmacal-relief-in-the-offshore-world-the-latest-developments-in-cayman-and-the-bvi","status":"publish","type":"post","link":"https:\/\/www.campbellslegal.com\/articles\/norwich-pharmacal-relief-in-the-offshore-world-the-latest-developments-in-cayman-and-the-bvi-5248\/","title":{"rendered":"Norwich Pharmacal Relief in the offshore world: the latest developments in Cayman and the BVI"},"content":{"rendered":"
In recent years, the offshore courts have shown a greater willingness to provide assistance to claimants or potential claimants by ordering third parties to disclose information about wrongdoing. Norwich Pharmacal<\/em> relief, the equitable principle by which the courts make orders for discovery against innocent third parties who are \u201cmixed up\u201d in the wrongdoing of others, has been used by common law courts for decades. It has become an increasingly attractive tool in the offshore world to assist with tracing assets and enforcing judgments or arbitral awards, particularly against registered agents who hold potentially valuable information about entities incorporated offshore.<\/p>\n History <\/strong><\/p>\n Norwich Pharmacal v Customs & Excise[1]<\/strong><\/a> <\/em>was decided by the House of Lords some 45 years ago. The leading speech of Lord Reid in that case has been referred to in numerous decisions as the starting point from which the jurisdiction has developed. In particular:<\/p>\n \u201c\u2026 if through no fault of his own a person gets mixed up in the tortious acts of others so as to facilitate their wrongdoing he may incur no personal liability but comes under a duty to assist the person who has been wronged by giving him full information and disclosing the identity of the wrongdoers\u2026 justice requires that he should co-operate in righting the wrong if he unwittingly facilitated its perpetration.\u201d <\/em><\/p>\n Traditionally, the three conditions to be satisfied for the court to exercise the power to order Norwich Pharmacal<\/em> relief were:<\/p>\n These principles have developed incrementally and there have been some inconsistencies and differences in respect of their application between courts in different jurisdictions. In general, however, and particularly in more recent times, the jurisdiction has been described in broader and more flexible terms.<\/p>\n In Ashworth Hospital[2]<\/strong><\/a><\/em>, it was said \u201cnew situations are inevitably going to arise where it will be appropriate for the jurisdiction to be exercised where it has not been exercised previously. The limits which applied to its use in its infancy should not be allowed to stultify its use now that it has become a valuable and mature remedy.\u201d<\/em><\/p>\n Developments to the traditional principles were summarised in the decision, Mitsui v Nexen Petroleum[3]<\/strong><\/a>, <\/em>where the English courts clarified that:<\/p>\n In light of these developments, Norwich Pharmacal <\/em>relief has been commonly used to identify a proper defendant to a claim or to obtain the information or evidence necessary to plead a claim. The cases emphasise the need for flexibility and discretion.<\/p>\n Cayman Islands<\/strong><\/p>\n The Chief Justice of the Grand Court of the Cayman Islands described the jurisdiction to make Norwich Pharmacal <\/em>orders as \u201cbroad, flexible and developing, and one in which a common sense non-technical approach would be taken.\u201d <\/em><\/p>\n The description of the jurisdiction in this way led to two important findings in Braga v Equity Trust<\/em>[4]<\/a> which demonstrate a development of the traditional principles:<\/p>\n Recent cases in the Grand Court suggest that the trend for the Cayman Islands is for disclosure to be ordered.<\/p>\n In these recent decisions, the Grand Court also considered important ancillary points, all of which further demonstrate the court\u2019s willingness to assist, rather than obstruct, victims of wrongdoing.<\/p>\n In Ramilos Trading[8]<\/strong><\/a><\/em>, the English court determined that a party seeking evidence in England to use abroad had to use the statutory mechanism and the availability of that mechanism precluded Norwich Pharmacal <\/em>relief. This decision (which has been applied in subsequent cases both on and offshore) has the potential ability to restrict the availability of the Norwich Pharmacal <\/em>jurisdiction.<\/p>\n In Arcelormittal v Essar[9]<\/strong><\/a><\/em>, the Grand Court accepted the reasoning in Ramilos <\/em>and confirmed that if<\/em> adequate relief can be obtained under the Evidence Order for obtaining evidence for use in foreign proceedings, the Cayman court\u2019s equitable jurisdiction to grant corresponding Norwich Pharmacal <\/em>relief falls away and is no longer available. However, on the facts, the court (making specific reference to the breadth and flexibility of the Norwich Pharmacal <\/em>jurisdiction) determined that the statutory remedy did not displace the equitable jurisdiction to grant the relief. Specifically, the court found that the Evidence Order was not engaged because the relief sought included (a) the preservation of documents, and (b) information needed to enable the plaintiff to determine whether the suspected wrongdoing (transferring assets to the prejudice of the creditor) had in fact occurred and, if so, to seek appropriate relief.<\/p>\n British Virgin Islands <\/strong><\/p>\n The Norwich Pharmacal <\/em>jurisdiction has also been broadened in the BVI in recent years, demonstrating a move away from the BVI Commercial Court\u2019s previous reluctance to grant such relief. In JSC BTA Bank v Fidelity[10]<\/strong><\/a>, <\/em>the Eastern Caribbean Court of Appeal found that a registered agent cannot, by virtue of its role in providing registered agent services to companies, , be considered a mere onlooker. The registered agent will usually be \u201cmixed up\u201d in the affairs of the principal company, and therefore the wrongdoing, for the purpose of a Norwich Pharmacal <\/em>application.<\/p>\n The scope has since been expanded further:<\/p>\n This is a particularly important development in the BVI, where the courts had been grappling with the extent to which Norwich Pharmacal <\/em>relief was available in support of foreign proceedings where a statutory mechanism was available. If Wallbank J\u2019s analysis is correct and followed in future cases, the statutory restriction would fall away (or not be engaged) because the duty of the person who has been mixed up in the wrongdoing to provide information to the victim would arise first. It is only after that duty arises, that the victim can approach the court for relief.<\/p>\n Conclusion <\/strong><\/p>\n The latest developments offshore confirm that the Norwich Pharmacal<\/em> jurisdiction is a powerful tool for victims of international fraud. The recent cases demonstrate that both the Cayman and BVI courts will not permit offshore structures to be used to misappropriate assets, and that a broad and flexible approach will be taken in ordering disclosure against innocent third parties, or wrongdoers themselves, to reveal information about the wrongdoing.<\/p>\n\r\n\t\t\t In recent years, the offshore courts have shown a greater willingness to provide assistance to claimants or potential claimants by ordering third parties to disclose information about wrongdoing. Norwich Pharmacal relief, the equitable principle by which the courts make orders for discovery against innocent third parties who are \u201cmixed up\u201d in the wrongdoing of others, has been used by common law courts for decades. It has become an increasingly attractive tool in the offshore world to assist with tracing assets and enforcing judgments or arbitral awards, particularly against registered agents who hold potentially valuable information about entities incorporated offshore.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"yst_prominent_words":[3658,3653,1125,3652,27,3655,3651,3656,3649,3548,3543,3545,3544,3549,3547,3546,3650,3657,3654,3659],"class_list":["post-5248","post","type-post","status-publish","format-standard","hentry","category-articles"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/posts\/5248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/comments?post=5248"}],"version-history":[{"count":16,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/posts\/5248\/revisions"}],"predecessor-version":[{"id":5641,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/posts\/5248\/revisions\/5641"}],"wp:attachment":[{"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/media?parent=5248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/categories?post=5248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/tags?post=5248"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/www.campbellslegal.com\/wp-json\/wp\/v2\/yst_prominent_words?post=5248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n
\n
\n
\n[2]<\/a> Ashworth Hospital Auth v MGN Ltd<\/em> [2002] 1 WLR 2033
\n[3]<\/a> Mitsui & Co. Ltd. V Nexen Petroleum UK Ltd. <\/em>[2005] EWHC 625 (Ch)
\n[4]<\/a> Braga v Equity Trust Company (Cayman) Limited and Four Others <\/em>[2011 (1) CILR 402]\n[5]<\/a> Discover Investment Company v Vietnam Holding Asset Management Limited & Saigon Asset Management Corporation <\/em>(unreported, Kawaley J, 5 November 2018)
\n[6]<\/a> Arcelormittal USA LLC v Essar Global Fund Limited & Essar Capital Limited <\/em>(unreported, Kawaley J, 29 March 2019)
\n[7]<\/a> In the matter between XYZ Ltd. and Genesis Trust & Corporate Services Ltd <\/em>(unreported, Kawaley J, 12 February 2019)
\n[8]<\/a> Ramilos Trading Limited v Buyanovsky <\/em>[2016] EWHC 3175
\n[9]<\/a> Arcelormittal USA LLC v Essar Global Fund Limited & Essar Capital Limited <\/em>(unreported, Kawaley J, 29 March 2019),
\n[10]<\/a> JSC BTA Bank v Fidelity Corporate Services Limited and others <\/em>HCVAP 2016\/035
\n[11]<\/a> UVW v XYZ (A Registered Agent),<\/em> (unreported, Wallbank J, 27 October 2016)
\n[12]<\/a> Rui Manuel v Harneys Corporate Services <\/em>BVIC HC (Com) 182 of 2017
\n[13]<\/a> Q v R Corp<\/em> (unreported, Wallbank, J, 13 December 2018)
\n\r\n\t\t\t<\/div>\r\n\t\t\n","protected":false},"excerpt":{"rendered":"